Carvedilol prevents myocardial fibrosis in hamsters

International Heart Journal

Volumn 47, Issue 4, 2006, Pages 607-616

  Nanjo, Shuji ^a   Yamazaki, Junichi ^a   Yoshikawa, Kohki ^b   Ishii, Toshiharu ^a   Togane, Yuko ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOMAZAWA UNIVERSITY   (Japan)

Author keywords

blocker therapy; Bio 53.58 hamster; MRI

Indexed keywords

CARVEDILOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCULATION; CONTROLLED STUDY; DRUG DOSE REGIMEN; ECHOCARDIOGRAPHY; HAMSTER; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE FIBROSIS; HEART PROTECTION; HISTOPATHOLOGY; MORTALITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCORING SYSTEM; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARBAZOLES; CRICETINAE; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FIBROSIS; HEART DISEASES; HEART VENTRICLES; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PROPANOLAMINES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33749061531     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.47.607     Document Type: Article

References (34)

1. Waagstein F, Hjalmarson A, Vamauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-36.
2. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-73.
3. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996; 94: 2800-6.
4. Packer M, Fowler MB, Roecker EB, et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-9.
5. Nanjo S, Yamazaki J, Yoshikawa K, Miura M, Seno A. Efficacy of contrast-enhanced MR imaging in cardiomyopathy: an experimental study using Bio14.6 hamsters. Acad Radiol 2002; 9: 1139-47.
6. Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990; 38: S82-8. (Review)
7. Nichols AJ, Gellai M, Ruffolo RR Jr. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol 1991; 5: 25-38.
8. Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995; 16: 38-42. (Review)
9. Homburger F. Myopathy of hamster dystrophy: history and morphologic aspects. Am NY Acad Sci 1979; 317: 2-17. (Review)
10. Bajusz E. Hereditary cardiomyopathy: a new disease model. Am Heart J 1969; 77: 686-96.
11. Strobeck JE, Facter SM, Bhan A, et al. Hereditary and acquired cardiomyopathies in experimental animals: mechanical, biochemical, and structural features. Ann NY Acad Sci 1979; 317: 59-88.
12. Whitmer JT. L-carnitine treatment improves cardiac performance and restores high-energy phosphate pools in cardiomyopathic Syrian hamster. Circ Res 1987; 61: 396-408.
13. Whitmer JT, Kumar P, Solaro RJ. Calcium transport properties of cardiac sarcoplasmic reticulum from cardiomyopathic Syrian hamsters (BIO 53.58 and 14.6): evidence for a quantitative defect in dilated myopathic hearts not evident in hypertrophic hearts. Circ Res 1988; 62: 81-5.
14. Farmer D, Higgins CB, Yee E, Lipton MJ, Wahr D, Ports T. Tissue characterization by magnetic resonance imaging in hypertrophic cardiomyopathy. Am J Cardiol 1985; 55: 230-2.
15. Zahler R, Chelman D, Gore J. Heterogeneous signal intensity in magnetic resonance images of hypertrophied left ventricular myocardium. Magm Reson Imaging 1989; 7: 517-28.
16. Nanjo S, Yamashina S, Yamazaki J. Evaluation of myocardial tissue characterization in dilated cardiomyopathy using MRI-Gd-DTPA radiography. J Cardiology 1994; 24 (Suppl): 153. (Japanese)
17. Wesbey GE, Higgins CB, McNamara MT, et al. Effects of gadolinium-DTPA on the magnetic relaxation times of normal and infarcted myocardium. Radiology 1984; 153: 165-9.
18. de Roos A, Doombos J, van der Wall EE, van Voorthuisen AE. MR imaging of acute myocardial infarction: value of Gd-DTPA. AJR 1988; 150: 531-4.
19. Wu AH, Das SK. Sudden death in dilated cardiomyopathy. Clin Cardiol 1999; 22: 267-72. (Review)
20. Cappato R, Negroni S, Bentivegna S, et al. Role of implantable cardioverter defibrillators in dilated cardiomyopathy. J Cardiovasc Electrophysiol 2002; 13: S106-9. (Review)
21. Hano O, Mitsuoka T, Matsumoto Y, et al. Arrhythmogenic properties of the ventricular myocardium in cardiomyopathic Syrian hamster, BIO 14.6 strain. Cardiovasc Res 1991; 25: 49-57.
22. Packer M, Coats AJ, Fowler MB, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8.
23. Homburger F. Myopathy of hamster dystrophy: history and morphologic aspects. Ann NY Acad Sci 1979; 317: 1-17. (Review)
24. Bajusz E. Hereditary cardiomyopathy: a new disease model. Am Heart J 1969; 77: 686-96. (Review)
25. Strobeck JE, Factor SM, Bhan A, et al. Hereditary and acquired cardiomyopathies in experimental animals: mechanical, biochemical and structural features. Ann NY Acad Sci 1979; 317: 59-88.
26. Sia YT, Parker TG, Tsoporis JN, Liu P, Adam A, Rouleau JL. Long-term effects of carvedilol on left ventricular function, remodeling, and expression of cardiac cytokines after large myocardial infarction in the rat. J Cardiovasc Pharmacol 2002; 39: 73-87.
27. Aso H. Evaluation of fibrosis in cardiomyopathy by Gd-DTPA contrast-enhanced magnetic resonance imaging: study of cardiomyopathic BIO14.6 hamsters. Mie Igaku 1995; 39: 65-74. (Japanese)
28. Munakata T. Histopathological significance of MRI enhancement effects in cardiomyopathic (BIO14.6) hamsters. JMRM 1998; 18: 286-97. (Japanese)
29. Runge VW, Clanton JA, Herzer WA, et al. Intravascular contrast agents suitable for magnetic resonance imaging. Radiology 1984; 153: 171-6.
30. Brash RC, Weinmann HJ, Wesbey GE. Contrast-enhanced NMR imaging: animal studies using gadolinium-DTPA complex. AJR 1984; 142: 625-30.
31. Robbin SL, Cotran RS, Kumar VP. Pathologic Basis of Disease. Philadelphia, PA, USA: W.B. Saunders;1984; 40-68.
32. Lotze U, Heinke S, Fritzenwanger M, Krack A, Muller S, Figulla HR. Carvedilol inhibits platelet-derived growth factor-induced signal transduction in human cardiac fibroblasts. J Cardiovasc Pharmacol 2002; 39: 576-89.
33. Barone FC, Campbell WG Jr, Nelson AH, Feuerstein GZ. Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. J Hypertens 1998; 16: 871-84.
34. Oshinski JN, Yang Z, Jones JR, Mata JF, French BA. Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging. Circulation 2001; 104: 2838-42.